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ABSTRACT
The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local drug
delivery, due to the lung’s favourable properties of a large surface area and high permeability.
Pulmonary drug delivery possesses many advantages, including non-invasive route of administration,
low metabolic activity, control environment for systemic absorption and avoids first bypass
metabolism. However, because the lung is one of the major ports of entry, it has multiple clearance
mechanisms, which prevent foreign particles from entering the body. Although these clearance
mechanisms maintain the sterility of the lung, clearance mechanisms can also act as barriers to the
therapeutic effectiveness of inhaled drugs. This effectiveness is also influenced by the deposition site
and delivered dose. Particulate-based drug delivery systems have emerged as an innovative and
promising alternative to conventional inhaled drugs to circumvent pulmonary clearance mechanisms
and provide enhanced therapeutic efficiency and controlled drug release. The principle of multiple
pulmonary clearance mechanisms is reviewed, including mucociliary, alveolar macrophages,
absorptive, and metabolic degradation. This review also discusses the current approaches
and formulations developed to achieve optimal pulmonary drug delivery systems.
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INTRODUCTION
Inhalation therapy has a long and rich history in the treatment of different respiratory diseases using
various natural inhalation remedies such as leaves from plants, vapors from aromatic plants, balsams,
and myrrh. Demand for developing tailor-made inhalable drug formulations increased, which, coupled
with advances in biology and engineering, have lead to a more optimized therapeutic efficiency1.
The pulmonary route of administration has gained a great deal of attention since the early 1990s as an
alternative to the parenteral route. At the beginning of 19th century, liquid nebulizers had been developed
and used as a legitimate inhalable pharmaceutical therapy. Examples of nebulizer drugs that had
been developed and investigated at this time were adrenaline, porcine insulin, penicillin and steroids.
The invention of liquid nebulizers paved the way for the development of various types of inhaler
devices. In 1956, the pressured metered dose inhaler (pMDI) was introduced and became the main
therapy for asthma. Despite advances in drug formulation technology, the majority of the inhalable
aerosol therapeutics suffer from limitations such as short half-life, and low bioavailability, resulting in
the necessity of increasingly frequent dosing. Consequently, there was an urgent need for an effective
inhalation therapy which could overcome these limitations and provide sustained therapeutic effect.
To formulate an effective inhalation therapy, the anatomy of the respiratory system, lung deposition
mechanisms and lung defense mechanisms should be fully understood2,4.
The respiratory system is divided into two main parts (Figure 1): the upper respiratory tract consisting
of nose, nasal cavity and pharynx and the lower respiratory tract consisting of larynx, trachea, bronchi,
alveoli, and lungs. Lungs are responsible for gas exchange throughout the body. Healthy lungs inhale
about 1 pint of air about 12-15 times every minute. The lungs are composed of five lobes; right lung
contains three lobes, while the left lung contains two lobes. The interior of the lung is comprised of
bronchi, alveoli, blood vessels and lymph nodes. The bronchi are divided into bronchioles which
branch in the lung, forming passageways for air, and terminate with the alveoli, which is responsible
for gas exchange5,6.
There are over 300 million alveoli in the lung, and each alveolus is lined with pulmonary capillaries
forming a huge network comprising over 280 billion capillaries, which provide a huge surface area of
about 70m2 available as a blood gas barrier. The alveolar gas exchangemainly occurred at the interface
consisting of alveolar epithelium, endothelium and interstitial cell layers, where the distance between
the capillaries and alveolar is very small, about 0.5mm, and thus facilitating gas exchange via diffusion.
Figure 1. Anatomy of respiratory system, A) shows different structures of the respiratory system. B) shows
airways, alveoli, blood vessels and capillaries. C) shows gas exchange between alveoli and capillaries8.
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The alveoli are coated with a layer of fluids and mucus, mainly composed of phospholipids and
surface proteins, which reduce the surface tension and are important for the proper functioning of gas
exchange. The lower respiratory passages are lined by a thin layer of connective tissue, surrounded
with different cells such as fibroblasts, nerves, macrophages and lymph vessels. Due to the uniqueness
of lung anatomy, it becomes a very appealing target for drug delivery of pulmonary and lymphatic
system, due to its large absorptive surface area, large absorptive mucosal membrane, and high
vascularity, forming a non-invasive route of drug administration6,8.
CHALLENGES FOR PULMONARY DRUG DELIVERY
The vast majority of current inhalation therapies suffer from a short half-life and low drug bioavailability
at the targeted site, resulting in a suboptimal therapeutic effect and severe side effects. The short half-
life and low drug bioavailability of inhaled drugs are due to three main clearance mechanisms
(1) pulmonary clearance includes mucociliary clearance and alveolar macrophages, (2) enzymatic
degradation, and (3) rapid systemic adsorption8,10.
1- Pulmonary clearance mechanisms
The primary function of the respiratory defense mechanism is to prevent foreign particles from entering
the respiratory system and to maintain it healthy and sterile. Similar to foreign particles, when aerosol
particles are administrated, the respiratory system eliminates the aerosol particles to avoid their
interaction with the lung cells, leading to therapy failure. Clearance mechanism of inhaled particles is
dependent on the deposition site within the lungs. For example, particles deposited in the
tracheobronchial tree are rapidly eliminated by mucociliary escalator, while particles deposited in
the lower alveolar region are cleared by macrophages9.
A- Mucociliary clearance
Mucociliary clearance is the primary defense mechanism in the upper respiratory tract. The upper airways
are lined with epithelial cells consisting of two layers: ciliated cells and goblet (mucus-producing) cells,
which both are known as a mucociliary escalator. The ciliated cells are covered with airway surface liquid
(ASL) and is composed of two layers; mucus layer and periciliary layer (PCL). The PCL layer provides a
desirable liquid environment which facilities the cilia displacement towardmucus clearance from the lung
to mouth. The principle of mucociliary escalator includes entrapment of the foreign/inhalable particles in
mucus layer before moving to the lower respiratory regions and then propelled along with mucus out of
trachea either by coughing or swallowing10,11. The mucociliary escalator eliminates the majority of the
inhaled particles of sizes greater than 6mm. On the contrary, smaller particles escape the mucociliary
escalator because they rapidly reach the epitheliumand preferentially deposit in the alveolar region, where
they dissolve or retain for long time span in the lungs. The mucociliary escalator provides an effective
clearance owing to its ability to balance between the function of ciliated cells and mucus-producing cells.
However, during lung infection or inflammation, the balance of mucociliary escalator disturbs resulting in
accelerating clearance of the inhaled drug and in turn reduces its retention time and effectiveness11,12.
B- Alveolar macrophage clearance
Beside the mucociliary escalator clearance, in the deep lung, such as alveoli, there is another powerful
clearancemechanism - the alveolar macrophages. The alveolar macrophages are phagocytic cells derived
frommonocytes and are present in large numbers in the lungs. Each alveolus is typically cleaned by 12-14
alveolar macrophages to keep it free from any foreign particles. Owing to the presence of alveolar
macrophages, the half-life of inhalable drugs within the alveoli cannot exceed a few hours, which in turn
results in an increasing dose frequency. It was also reported that alveolar macrophages engulf particles of
sizes rangedbetween 1.5-3mm9. This size-discriminating property has beenusedas a basis for formulating
inhalable drugs, which can escape the alveolar macrophages and provide a controlled drug release in the
deep lung. Although the alveolar macrophage clearance seems to be understood, the exact mechanism
behind particle uptake, transport, and clearance in the alveolar epithelium is still unknown12–14.
2- Enzymatic degradation
Inhaled drugs are also highly susceptible to enzymatic degradation in the lung, resulting in a
suboptimal therapy. The primary detoxification enzyme in the lung are the cytochrome P450 (CYP)
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families, which provide a line of defense against ingested or inhaled xenobiotics. There are several CYP
isoforms expressed in the lungs15, which are able to degrade a broad spectrum of chemically-different
inhalable drugs, pollutant, toxicants, etc. Several inhaled drugs such as budesonide, ciclesonide,
salmeterol, and theophylline are enzymatically degraded in the lung. In addition, peptide/proteins
drugs such as insulin are highly vulnerable to peptidase and proteases enzymes present in lung.
Although the lung has a low metabolic activity, compared to other organs such as the liver, enzymatic
degradation significantly influences a drug’s bioavailability at the lung, and hence should be carefully
assessed during drug formulation5,12.
3- Rapid systemic absorption
Another significant challenge facing inhalation therapeutics is their rapid systemic absorption from
the lung. The rapid systemic absorption is ascribed to the lung’s large surface area, good epithelial
permeability and high vascularity, as well as the highly dispersed nature of therapeutic aerosols.
The optimal absorption of inhalable aerosol relies on their site of actions, either locally or systemically.
Therefore, to achieve an ideal local effect, an inhaled drug must be absorbed and terminated in the
lung, whilst any systemic absorption results in a rapid elimination of the drug and adverse side effects.
On the other hand, the systemic effect is achieved when the inhaled drug is systemically absorbed
from the lung into blood stream. The air-to-blood transfer of inhalable drugs often starts with the
interaction between the drug and the surfactant after deposition on the mucosa of tracheobronchial
airways or alveolar region. This interaction is greatly influenced by the drug’s nature, and determines
whether the drug is absorbed or eliminated. For instance, the contact between peptide drugs and lung
surfactant causes particle aggregations, which in turn compromise their dissolution and accelerate
their clearance via alveolar macrophage12 (Figure 2).
On the contrary, the contact between small lipophilic drugs (i.e. glucocorticosteroids) and lung surfactant
improves their solubility and increases their rate and extent of absorption13,14. Immediately below the lung
surfactant layer, there is a 0.01-10mm thick lining layer where the drug can diffuse to the epithelium,
followed by interstitum and eventually diffuse to blood stream16. The mechanisms of systemic drug
absorption includepassive and active transportmechanismssuch asparacellular or transcellular transport
pore formation, vesicular transport and lymphatic drainage. The mechanisms of drug absorption across
the epithelium are highly dependent on the drug nature, molecular weight and the targeted site5,17.
Studies reported that small lipophilic and hydrophobic drugs are comprehensively absorbed within 1-
2minutes from the lung into the systemic circulation viapassivediffusion,while small hydrophilic drugs are
absorbed within 65minutes, through the tight junction. Studies also found that hydrophilic and highly
cationic small molecules exhibit a prolonged absorption5,11,17–20. Beyond these facts, the systemic
adsorption of some drugs such as peptide drugs is still unclear. However, some speculated mechanisms
stated that the absorption of peptide drugs take place either via transcytosis through caveoli or
paracellularly through the tight junctions. Themajority of researchers suggest that absorption through the
tight junction is the predominant mechanism for peptide drugs. Consequently, these findings claim that
drug absorption site and mechanism should certainly be considered while designing inhalation therapy
in order to achieve an optimum lung-tissue retention and permeability6,9,19–22.
SIGNIFICANCE OF PARTICULATE-BASED PULMONARY DRUG DELIVERY
As a result of the strong pulmonary clearance mechanisms and rapid systemic absorption, inhaled
drugs exhibit low bioavailability at the lungs. The low drug bioavailability at the lung represents the
Figure 2. The deposition mechanism and uptake of particles in the lungs along with different cell types6.
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main obstacle toward formulating inhaled drugs with high therapeutic efficiency and sustained drug
release. Since drug bioavailability at the targeted site (lung) is considered the key factor for optimal
therapy, as it determines whether a drug causes a complete treatment or a partial treatment with high
toxicity, several approaches have been developed to overcome the rapid drug absorption and prolong
its half-life5. Among different approaches, particulate-based drug delivery systems which rely on using
carriers, which encapsulate the inhaled drug, seem to be advantageous for pulmonary delivery over
other approaches. The advantages of particulate-based drug delivery include (1) protect the drug from
enzymatic degradation, (2) evade pulmonary clearance, (3) slow the drug absorption, (4) deliver the
drug to targeted site at the lungs, (5) provide a controlled drug release, (6) reduce dose frequency,
(7) maximize the therapeutic efficiency, and (8) minimize adverse side effects.
To achieve such inhalation therapeutic formula, several factors such as aerodynamic diameters,
shape and surface properties of carriers should be tailored and optimized. Researchers from
multidisciplinary fields such as chemistry, biology, toxicology, and biomaterials science heavily studied
and investigated these factors in an attempt to identify the optimal parameters for developing
an effective particulate-based pulmonary drug delivery system5,6,21–23.
FACTORS INFLUENCING PULMONARY DRUG DEPOSITION AND BIOAVAILABILITY
1- Particle size
In an attempt to evade both clearance mechanisms and simultaneously provide an effective therapy,
several studies were conducted to identify the factors affecting drug bioavailability and deposition.
It was found that modulating the particle size of an aerosol could deliver the drug to its targeted site
and evade pulmonary clearance. Aerosols, inhalable suspensions composed of solid or liquid particles
in a gas, are a form of particulate matter (PM). PM is referred to chemically heterogeneous disperse
liquid droplets or solid particles, within the micro-scale (Figure 3). The size of PM in an aerosol can
range from 0.001 to more than 100microns. The aerosol particles can be divided into (1) ultrafine
particles (less than 0.1mm), (2) fine particles (0.1-2mm), and (3) coarse particles (greater than 2mm)5.
The size of PM in aerosols plays a pivotal role in determining their deposition site and mechanism at
the respiratory system. The mechanisms of respiratory deposition are classified based on particles
sizes into different mechanisms, namely diffusion, sedimentation, impaction, and interception5,9.
Particles with sizes smaller than 0.5mm are deposited in the alveoli by diffusion mechanism.
Diffusion is defined as the movement of particles from a region of high concentration to a region of low
concentration owing to Brownian motion. Brownian motion is a random wiggling motion of particles
due to the constant bombardment of air molecules. However, the majority of the particles are exhaled
owing to their small size (,0.5mm)5,22–24.
Sedimentation is another deposition mechanism, which plays a significant role in the setting out
particles of aerodynamic size between 1-5mm in the smaller airways of bronchioles and alveoli where
Figure 3. Particle size determines the particles deposition site at the lung. Adapted from reference 79.
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the airflow is low. Sedimentation is governed by gravitational forces, particle velocity and aerodynamic
size. Moreover, sedimentation is influenced by breathing pattern, where slow breathing provides a long
time span for particles to slowly deposit. It was also speculated that sedimentation is main deposition
mechanism of hygroscopic particles, particles which grow in size after passing through warm and
humid air passages. For example, nanoparticles released from the aerosol bypass the warm
humid airways aggregating and forming particles of micro-sizes, which allow their deposit in the
bronchiolar region24,25.
Particles with sizes greater than 5mm are deposited at the bronchial regions by impaction. Impaction
is highly dependent on aerodynamic diameter and mass. Impaction is the common deposition
mechanism for dry powder inhalation (DPI) and metered dose inhalators (MDI)5.
Interception is based on the physical size and shape of particles contacts the airway surface.
In contrast to impaction, particles deposited by interception did not deviate from their air
streamlines26. Interception commonly occurred at the small airways or when the air streamlines near to
an airway wall. Interception is responsible for fiber deposition at the smallest airways owing to their
small aerodynamic diameters relative to their sizes6,24.
Despite the tunable size of inhaled particles, which permits particles to deposit at the targeted site in
the respiratory system, lung clearance mechanisms represent the main obstacle facing inhalation
therapy. It was also revealed that the particle’s aerodynamic diameter, a diameter of sphere with
density of 1 g/cm3 with settling velocity similar to irregular particles, is the key factor, which can be
manipulated to circumvent mucociliary and macrophage clearance mechanisms. The main challenge
facing inhaled therapeutics is the mucociliary clearance and alveoli clearance, which exaggerate
during lung diseases resulting in therapy failure. Studies reported that the particles with aerodynamic
sizes between 1-5mm could escape the mucociliary clearance and deposit in the lower airways.
This aerodynamic size range is currently employed in many commercial inhalation aerosols commonly
used for the treatment of asthma, such as terbutaline and salbutmol aerosols with aerodynamic
diameter of 1.8-2.8mm. Usami et al. recently formulated mono-dispersed aerosols, which have proven
great preferential deposition ability in the deep lung. Although particles of aerodynamic sizes between
1-5mm are able to escape the mucociliary clearance and deposit in the deeper lungs, it was found
that they are rapidly eliminated by alveoli macrophage27,28.
A particulate-based drug delivery system is a promising alternative approach, which depends on
modulating the aerodynamic diameter of drug carriers to circumvent the alveoli macrophage and
simultaneously deliver and release the drug into the deep lungs. One successful example of
particulate-based drug delivery system includes the use of large porous microparticles (LPPs) with size
greater than 5mm, but with a density of about 0.1 g/L or less. The LPPs showed an appealing ability to
escape macrophage uptake and deposit homogeneously at the deep lungs. Nanoparticles (NPs) have
also been used as a drug carriers for overcoming mucociliary clearance and alveolar macrophages.
Studies showed that NPs can deposit at the lining fluid and escape both mucociliary clearance and
alveolar macrophages29,30. Although NPs seems to be advantageous for pulmonary delivery, their
small sizes mean they are predominantly exhaled after inhalation. In order to overcome such an issue,
a new particulate-based pulmonary drug delivery system has emerged based on encapsulating
drug-loaded NPs in microparticles, known as “Trojan” particles. Trojan particles have shown a great
ability in delivering and releasing NPs in the peripheral airways, hence evading the pulmonary
clearance and offering a sustained drug release. Trojan particles are typically produced by spray drying
of NPs, followed by their assembly into hollow microparticles of low density (,0.1 g/L)31. Although
increasing the sizes of microparticles decreases their susceptibility to the alveolar macrophages
clearance, this solution is restricted because the increase of microparticles’ sizes reduces the delivered
respirable fraction.
In an attempt to overcome this challenge, a more recent particulate-based pulmonary drug delivery
system has been developed by El-Sherbiny et al., relying on smart stimuli-responsive microparticles as
carriers for drug-loaded NPs32,33. These smart microparticles are swellable, with sizes between 1-5mm
in the dry state, while in moisture - such as in the warm and humid airways - they absorb water and
swell, therefore they can preferentially deposit in the deep lung and escape the macrophage clearance.
For instance, El-Sherbiny et al. (Figure 4) developed smart microparticles composed of PEG grafted
onto chitosan crosslinked hydrogel and combined with Pluronic F-108 for pulmonary delivery. In-vitro
studies showed that the microparticles swell in a controllable manner forming larger particles, which
cannot be engulfed by macrophage cells32. El-Sherbiny et al. also formulated sodium alginate-based
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microspheres encapsulating hybrid PEG grafted onto N-phthaloylchitosan and chitosan/hyaluronic
acid nanoparticles for deep pulmonary drug delivery. The characterization studies revealed that
nanoparticles are well-dispersed and completely encapsulated within the swellable microcarriers33.
2- Particle shape and orientation
In addition to particle size, it was reported that particle shape also influences the alveolar macrophage
clearance. Champion and Mitragotri developed non-opsonized and opsonized geometrically IgG
anisotropic polystyrene (PS) particles of various sizes and shapes, such as spheres, rectangular disks,
elliptical disks and oblate ellipsoids. The in-vitro study showed that the shape and orientation of
particles significantly influences the phagocytosis of both non-opsonized and opsonized particles.
Figure 5. Scanning electron micrographs (A-C) and actins staining (D-F) explain the effect of particle shape on
macrophages uptake34.
Figure 4. Schematic illustration of the smart swellable microparticles32.
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Scanning electron microscope (SEM) results demonstrated that macrophages exhibit orientation bias,
where phagocytosis occurs in less than 6minutes when macrophages attached to the major axis of
elliptical disks. On the contrary, macrophages attached to the minor axis or flat surface of elliptical
disks, cannot engulf the particles even after 2 hrs. Similar results have been reported to other shapes
including rectangular disks and oblate ellipsoids, but it was not the case for spheres because they are
rapidly engulfed by the macrophages regardless the attachment point34 (Figure 5). The same research
group conducted another in-vitro study to evaluate the effect of worm-like particles on macrophages
uptake using time-lapse video microscopy and fluorescence microscopy. Spherical and worm-like
particles were prepared and tested on rat macrophage cell line. The in-vitro study confirmed that
worm-like particles exhibit negligible phagocytosis compared to spherical particles due to low
curvature region of worm-like particles. Macrophages engulf the worm-like particles only when
attached to the major axis, which exhibits high curvatures, while attachment anywhere along the
particles’ length inhibits the macrophage engulfment due to the low curvature35.
3- Stealth characteristics
In order to avoid rapid drug absorption, degradation, and evade the pulmonary clearance as well as
simultaneously prolong inhalable drug’s half-life at the lung, inhaled drugs with stealth characteristics
were developed. Stealth characteristics are achieved by attaching or coating the drugs with a stealth
material. The stealth material forms a hydration layer over the drug which prevents biofouling and
immune recognition36. For example, hyaluronic acid (HA), a mucoadhesive polysaccharides present in
lung, is combined with inhaled drugs. HA-conjugated drug suppresses the phagocytosis and provides a
prolonged drug effect at the lung37. Surendra Kumar et al. in-vivo evaluated the release of insulin from
inhaled HA-based dry powder. The inhaled HA-coated insulin-loaded microparticles demonstrated a
prolonged mean residence time and half-life compared to unmodified inhaled insulin38. Evora et al.
also found that peroxidase-loaded PLGA microspheres coated with lipid dipalmitoylphosphatidyl-
choline (DPPC) reduces the macrophage uptake of protein peroxidase39. Recently, polyethylene glycol
(PEG) is being widely used as a coating of micro/nanocarriers for different drug delivery purposes.
PEG provides stealth characteristics by forming a hydration layer over the NPs that sterically prevents
biofouling and phagocytosis40. Niven et al. found that PEGylated rhG-CSF possesses a prolonged
pulmonary effect and are nontoxic. Nektar Company also uses PEGylated particulate-based drug
delivery system to develop long acting inhaled insulin41,42.
TYPES OF PARTICULATE-BASED PULMONARY DRUG DELIVERY SYSTEMS
Particulate-based pulmonary drug delivery systems offer great opportunities to formulate local and
systemic targeted therapy for various diseases such as respiratory diseases, diabetes, and cancer
therapy. Several types of carriers have been used for formulating various particulate-based pulmonary
drug delivery systems attempting to optimize drug loading, residence half-life, drug release, toxicity
and simultaneously overcome the multiple lung clearance mechanisms, enzymatic degradation, and
rapid systemic absorption. Therefore, the selection of drug carriers is of significant importance, but
several other factors such as physicochemical properties of the drug, the used inhaled device, targeted
site, diseases status, the nature and safety of the carrier should also be considered24,43.
LIPOSOMES
Recently, liposomes have become a focus of research in pulmonary drug delivery applications owing to
their potential advantages including biocompatibility, biodegradability, sustained drug release, and
reduce local irritation. Liposomes are mainly produced from natural or synthetic phospholipids that
have either no charge, or net positive/negative charge. The commonly used phospholipids are
lecithins, phosphatidylethanolamines, sphingomyelins, phosphatidyl glycerol and phatidylserines44.
The structure of liposomes consists of an aqueous volume surrounded by a single layer or bilayer of
lipid and is capable of encapsulating either hydrophobic or hydrophilic drugs. Liposomal-based
formulations can be prepared either as a liquid or in a dry powder form. The deposition site of
liposomes and drug release rate are based on liposomes’ composition and size, charge, drug/lipid
ratio, and method of delivery. Therefore, liposomal-based aerosol formulations can be tailored to
deliver the drug to a specific area within the lung by changing its composition or the preparation
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method45. The first liposomal product in the market is the Alveofactw, which is used the treatment of
respiratory distress syndrome19.
The advances in the development of liposomal-based aerosol formulations with jet nebulizers has
opened up new possibilities for effective use of aerosols in the treatment of various pulmonary
diseases5,46. Studies revealed that liposomal-based aerosol formulations enhanced the drug stability
and bioavailability, protected the drug from enzymatic degradation, prolonged the retention half-life,
allowed intracellular delivery and over came pulmonary clearance47. Nieminen et al. in-vivo studied the
absorption, drug release, and clearance of liposomes encapsulating cyclosporine A (CsA). Results
obtained from this study demonstrated that the retention time of CsA-liposomes was 16.9-fold longer
than free CsA in normal lung and 7.5-fold longer in inflamed lung48. Arppe et al. developed CsA
encapsulated in liposomal for pulmonary delivery and compared its retention time with free CsA.
It was reported that the retention time of free drug was 17minutes, while liposomal aerosol was about
4.8 hrs49. In another study, formulation of CsA and paclitaxel with PEGylated liposomes provided
evidence of an enhanced drug deposition and increased therapeutic index by sustaining the
therapeutic action in the lung.
Poyner et al. conducted also comparative study between tobramycin-loaded PLA-microparticles and
tobramycin-loaded liposomes administrated by endotracheal and intravenous delivery. The renal
elimination of the intravenously administrated tobramycin-loaded PLA microparticles was higher than
tobramycin-loaded liposomes after 6 and 24 hrs. On the other hand, endotracheal administrated
tobramycin-loaded liposomes demonstrated pulmonary level 3-fold higher than free drug after 6 and
24 hrs50. Gibbons et al. encapsulated leukocyte protease inhibitors (rSLPI) in liposomal for pulmonary
delivery to enhance the bioavailability of rSLPI. In fact, the study showed that the bioavailability of
rSLPI-liposomes at the lung significantly increased and reached about 92.6%51. Shahiwala and Misra
compared the bioavailability of intratracheally and orally administrated levonogestrel-liposomal
formulation and free drug. The study showed that the intratracheally administrated levonogestrel-
liposomal maintained the effective therapeutic concentration in plasma over 6-60 hrs, which can
decrease the dose frequency and adverse side effects52. PEGylated liposomes have been developed
and used for pulmonary drug delivery system to benefit from the stealth effect and achieve a prolonged
circulation half-life. Nag et al. showed that PEGylated-liposomes exhibited a prolonged circulation time
compared to uncoated-liposomes. The in-vivo study conducted on rabbits also showed that PEGylated
liposomes with sizes of 275 nm exhibita prolonged circulation half-life13,44,53.
SOLID-LIPID NANOPARTICLES
Solid-lipid nanoparticles (SLN) are submicron-sized nanocarriers consisting of monolayer phospholipid
shell and solid hydrophobic core. SLNs are widely used as carriers for many drugs for both local and
systemic delivery54. For pulmonary delivery, several studies examined the potential of SLNs using
human alveolar epithelial cell line (A549) and murine precision-cut lung slices (PCLS). The study
showed that SLNs cause no signs of inflammation and thus confirming the suitability of SLNs as
drug carriers for pulmonary delivery55,56. SLNs have been also used for pulmonary delivery of insulin
and demonstrated high in-vitro and in-vivo stability of insulin and a prolonged therapeutic effect57.
In another study, itraconazole (ITZ)-loaded SLNs colloidal dispersion showed a great suitability for
nebulization with proper aerodynamic properties for upper and lower lung delivery. The bioavailability
of itraconazole (ITZ)-loaded SLNs was increased by reducing the particle size, which increases
permeation and dissolution rate58. The rate of drug encapsulation within SLNs also depends on many
factors which should be considered during preparation such as (1) the drug solubility into lipids,
(2) the miscibility of the drugs into lipids, (3) chemical and physical structures of the lipid-solid matrix,
and (4) the polymorphous state of the lipids.
PEGylated SLNs have been developed and showed a great potency in enhancing the drug stability
and bioavailability at the lung. Ligands-conjugated cationic SLNs have also been developed and
in-vitro examined on alveolar macrophages. The study demonstrated that ligands-conjugated
cationic SLNs exhibit an efficient DNA hybridization through ionic interaction and induce site-specific
gene transfection on alveolar macrophages46. Other drugs such as prednisolone, diazepam and
camptotecin have been encapsulated into SLNs for pulmonary delivery applications59. Torjan approach
has been also applied for enhancing the pulmonary delivery of SLNs. Microparticles encapsulating
thymopentin-loaded SLNs were prepared using co-spray-drying. The prepared microparticles
containing drug-loaded SLNs were spherical and showed significant aerosolization efficiency.
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The bioavailability and therapeutic effectiveness of the intratracheally administrated microparticles
containing drug-loaded SLNs found to be significantly higher than free drug60,61.
POLYMERIC MICRO/NANOPARTICLES
The polymeric microparticles are spheres with size ranged between 1-1000mm, while nanoparticles are
spheres with size ranging from 1-1000 nm. Polymeric micro/nanoparticles are mainly produced from
natural or synthetic biocompatible and biodegradable polymers such as chitosan, poly(lactic-co-
glycolic) acid, poly(lactic) acid, poly(butylcyanoacrylate), and poly(lactic-co-lysine graft lysine)5,46,62.
The utilization of polymeric micro/nanoparticles offers potential advantages over other carriers such
as liposomes, because of their higher stability, higher drug loading capacity, slower drug release
and longer pharmacological activity of payloads. Moreover, the properties of polymeric
micro/nanoparticles such as morphology, size, and porosity can be easily tailored to meet the
requirement of pulmonary delivery62,63.
Microparticles are frequently used for pulmonary delivery because they preferentially deposit in the
deep lung and do not aggregate under shear force. Different drugs such as corticosteroids, insulin, and
chemotherapeutics have been formulated within polymeric microparticles63. Insulin-PLGA micro-
particles have been developed and showed a prolonged residence time extended from 6-48 hrs
compared to free insulin64. Wang et al. developed and examined the effect of docetaxel (DTX)-loaded
chitosan microspheres in-vitro and in-vivo. The prepared microspheres were mono-dispersed and
spherical in shape with drug encapsulation efficiency about 88%. The in-vitro and in-vivo studies
showed that DTX was sustainably released, which increases its bioavailability at the lung, while
minimizing the systemic toxicity65.
On the other hand, polymeric nanoparticles-based aerosols have been recently formulated and
studied in-vitro and in-vivo66. For example, poly butylcyanoacrylate (PCL) nanoparticles are widely
used for pulmonary delivery owing to its safety, biocompatibility and biodegradability. Effervescent dry
powder containing ciprofloxacin-loaded PCL nanoparticles have been produced by spray drying.
The prepared ciprofloxacin-NPs evolved with aerodynamic diameter of 2.71mm and released 56%
of ciprofloxacin. Due to the rapid exhalation of nanoparticles, Grenha et al. developed chitosan
nanoparticles encapsulated into mannitol microspheres and in-vitro tested on respiratory epithelium
cells. The In-vitro study showed that chitosan nanoparticles encapsulated microspheres have good
aerodynamic properties, high drug loading efficiency and exhibit high biocompatibility, which confirm
their potential for formulating an efficient pulmonary drug delivery system67.
Studies showed that inhaled anticancer drugs can be efficiently delivered to lung parenchyma, which
in turn selectively treat lung cancer and reduce the systemic toxicity. 5-flurouracil has been formulated
into lipid-coated nanoparticles and showed a sustained drug release and potent anticancer activity
against lung cancer. Recently, nano-in-macro (SIMANIM) particles have been developed and applied
for pulmonary delivery of antibodies. These SIMANIM particles were prepared by spray drying of a
double-emulsion containing IgG antibodies. The in-vitro release of antibodies at pH 2.5 was monitored
for 35 days and the activity of the released antibodies was tested using gel electrophoresis and
enzyme-linked immunosorbent assay. Both assays confirmed the stability and efficiency of the
released antibodies even after 35 days68.
MICELLES
Micelles are aggregates of surfactant molecules dispersed in a liquid solution. Polymeric micelles,
amphiphilic macromolecules self-assemble to core-shell nanostructure in aqueous solution, are the
most common type of micelles used in drug delivery applications because of their better stability,
higher tendency of micellization, slower dissolution rate, longer circulation half-life and non-toxicity.
The polymeric micelles are similar to the structural and functional properties of biological transport
systems such as virus and lipoproteins. The polymeric micelles offer many advantages in drug delivery
because of their distinctive structure and physico-chemical properties.
Micelles are composed of a hydrophilic shell which allows them to escape the reticulo-endothelial
system and therefore exhibit a prolonged their circulation half-life. The small sizes of micelles
(100–400 nm) also facilities their cellular uptake69,70. The structure of polymeric micelles can also be
chemically altered to design ideal delivery carriers that can improve drug stability, control drug release,
and provide targeted drug delivery71.
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Jones and Leroux formulated inhaled beclomethasone dipropionate-loaded polymeric micelles
within nano-sizes for the treatment of asthma and chromic pulmonary obstructive diseases.
This study revealed that the prepared drug-loaded polymeric micelles were able to evade the alveolar
macrophages due to their hydrophilic shells, and in turn provide sustained drug release. It was
also reported that the drug-loaded polymeric micelles pass through the mucus layer, penetrate the
epithelial cells, and eventually reach the inflamed site. This finding indicates that polymeric micelles
could be ideal carriers for hydrophobic corticosteroids such as beclomethasone dipropionate, which
are used for the treatment of chronic pulmonary obstructive diseases: the main reason behind the
failure of chronic pulmonary obstructive therapy is the inability of drug to pass through the mucus layer
associated with bronchial inflammatory diseases and reach the inflamed site5. Gaber et al. also
developed beclomethasone dipropionate-loaded poly-(ethyleneoxide)-block-distearoylphosphatidyl-
ethanolamine (mPEG-DSPE) polymeric micelles. The prepared drug-loaded mPEG-DSPE micelles
showed high drug entrapment efficiency, sustained drug release and high therapeutic efficiency,
which reflects the potency of polymeric micelles in delivering the hydrophobic corticosteroids to
the inflamed site5,72.
CYCLODEXTRINS
Cyclodextrins (CDs) are cyclic polymers of a-D-glycopyranose composed of cyclic oligosaccharides.
There are three types of CDs; a-, b- and g-CDs, the b-CDs are commonly used for pharmaceutical
applications because of their high loading capacity, high complexation efficiency and low production
cost. CDs are extensively used as drug carriers for pulmonary delivery due to their unique structure,
composed of an outer layer containing hydroxyl groups, and a lipophilic inner cavity, which allows the
formation of an inclusion complex with the hydrophobic drugs. The formation of the inclusion complex
results in enhancement of the aqueous solubility of the payload drug46,73. CDs can also behave as
solubilizers in aerosol formulations of lipophilic water-insoluble drugs to decrease the drug irritation
following pulmonary delivery47,74. Moreover, the CD complexes aid in enhancing the drug delivery
through biological barriers without influencing their barrier function. These properties render CDs
an ideal penetration enhancer for intranasal drug delivery74.
An aerosol formulation of itraconazole (ITZ)-loaded on 2-hydroxy-propy-beta-cyclodextrins
(HPbetaCDs) has been developed for pulmonary delivery. The pharmacokinetic profile of ITZ-
HPbetaCDs was investigated in comparison with colloidal dispersion of ITZ-loaded nanoparticles.
This study revealed that ITZ-HPbetaCDs exhibit faster systemic absorption across the lung epithelium
compared to ITZ nanoparticles75. In another study, nebulized solution of voriconazole complex-
ed-sulfobutyl ether-beta-CDs has been developed for targeted pulmonary drug delivery. It was found
that voriconazole complexed-sulfobutyl ether-beta-CDs exhibit fast absorption and high bioavailability
after pulmonary administration76. CDs are also used in combination with other carriers in order to
enhance the drug encapsulation efficiency and provide a controlled drug release. Hydroxypropyl-
beta-CDs have been employed for the development of large porous PLGA-loaded insulin. The prepared
CD-based PLGA-loaded insulin demonstrated a high bioavailability and prolonged therapeutic
effect compared to free insulin77. An inhalable dry powder of recombinant human growth hormones
solubilized with dimethyl-beta-CD has also been formulated for systemic delivery. The in-vivo studies
showed that the inhaled dry powder exhibits an excellent aerosol performance and rapid systemic
absorption after pulmonary administration to the rat lung78.
CONCLUSION
The lung is a very promising target either for local or systemic therapies owing to its large surface area,
lower metabolic activity, and the fact that it avoids the first pass metabolism. The main obstacles facing
the development of successful pulmonary drug delivery are pulmonary clearance mechanisms,
rapid systemic absorption, metabolic degradation and control over drug deposition site and rate.
To circumvent these obstacles, particulate-based pulmonary systems were developed based on the
use of different carriers such as liposomes, solid lipid nanoparticles, polymeric micro/nanoparticles,
micelles, and cyclodextrins. The particulate-based pulmonary systems demonstrated a great potency in
enhancing the drug bioavailability and therapeutic effectiveness at the deep lung. Ongoing research
focusing on exploring and understanding the complexity of lung will help in identifying many matters
such as the molecular basis of pulmonary diseases and the challenges facing pulmonary drug delivery.
The knowledge and understanding of these matters could aid in formulating an efficient and safer
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pulmonary delivery systems. Therefore, a lot of effort is still needed to minimize the clinical and
technical gaps to enable translating these particulate-based pulmonary approaches into commercial
pharmaceutical products.
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